Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (89) 89
oncology (81) 81
female (78) 78
middle aged (75) 75
aged (70) 70
adult (65) 65
chemotherapy (55) 55
index medicus (46) 46
cancer (42) 42
antineoplastic combined chemotherapy protocols - therapeutic use (37) 37
male (34) 34
breast cancer (32) 32
treatment outcome (31) 31
paclitaxel (30) 30
aged, 80 and over (29) 29
prognosis (28) 28
breast neoplasms - drug therapy (26) 26
human (21) 21
research (21) 21
article (20) 20
epirubicin (20) 20
therapy (20) 20
trial (20) 20
antineoplastic combined chemotherapy protocols - adverse effects (19) 19
carcinoma (19) 19
disease-free survival (19) 19
ovarian cancer (18) 18
priority journal (18) 18
antineoplastic combined chemotherapy protocols (17) 17
carboplatin (17) 17
colorectal cancer (17) 17
paclitaxel - administration & dosage (17) 17
cisplatin (16) 16
medicine (16) 16
neoplasm staging (16) 16
survival (16) 16
survival analysis (16) 16
survival rate (16) 16
antineoplastic combined chemotherapy protocols - administration & dosage (15) 15
chemotherapy, adjuvant (15) 15
cyclophosphamide (15) 15
major clinical study (15) 15
breast neoplasms - pathology (14) 14
controlled study (14) 14
genetic aspects (14) 14
mutation (14) 14
young adult (14) 14
clinical trials (13) 13
fluorouracil (13) 13
oncology, experimental (13) 13
tumors (13) 13
breast neoplasms - genetics (12) 12
drug administration schedule (12) 12
ovarian neoplasms - drug therapy (12) 12
oxaliplatin (12) 12
research article (12) 12
retrospective studies (12) 12
anemia (11) 11
antineoplastic agents (11) 11
breast neoplasms - mortality (11) 11
cancer survival (11) 11
cancer therapies (11) 11
clinical trial (11) 11
health aspects (11) 11
immunohistochemistry (11) 11
patients (11) 11
protein expression (11) 11
analysis (10) 10
carboplatin - administration & dosage (10) 10
dose-response relationship, drug (10) 10
doxorubicin (10) 10
fluorouracil - administration & dosage (10) 10
gemcitabine (10) 10
greece (10) 10
medical prognosis (10) 10
medicine & public health (10) 10
metastasis (10) 10
neutropenia (10) 10
antineoplastic agents - therapeutic use (9) 9
care and treatment (9) 9
drug therapy (9) 9
hematology, oncology and palliative medicine (9) 9
hospitals (9) 9
medical research (9) 9
ovarian neoplasms - pathology (9) 9
prospective studies (9) 9
advanced cancer (8) 8
alopecia (8) 8
breast neoplasms (8) 8
cancer chemotherapy (8) 8
cancer patients (8) 8
cancer research (8) 8
colorectal neoplasms - drug therapy (8) 8
combination (8) 8
cyclophosphamide - administration & dosage (8) 8
dense sequential chemotherapy (8) 8
diarrhea (8) 8
drug efficacy (8) 8
expression (8) 8
kaplan-meier estimate (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: A systematic review
by Aravantinos, Gerasimos and Pectasides, Dimitrios
Journal of Ovarian Research, ISSN 1757-2215, 05/2014, Volume 7, Issue 1, p. 57
As increased angiogenesis has been linked with the progression of ovarian cancer, a number of anti-angiogenic agents have been investigated, or are currently... 
Targeted therapies | Angiogenesis | Primary peritoneal cancer | Fallopian tube cancer | Bevacizumab | Ovarian cancer | FALLOPIAN-TUBE | OPEN-LABEL | WEEKLY PACLITAXEL | PHASE-II TRIAL | REPRODUCTIVE BIOLOGY | DOUBLE-BLIND | SUNITINIB | TYROSINE KINASE INHIBITOR | RECURRENT EPITHELIAL OVARIAN | PRIMARY PERITONEAL | ENDOTHELIAL GROWTH-FACTOR | Humans | Angiogenesis Inhibitors - pharmacology | Neovascularization, Pathologic - diet therapy | Molecular Targeted Therapy | Randomized Controlled Trials as Topic | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antibodies, Monoclonal, Humanized - pharmacology | Female | Ovarian Neoplasms - blood supply | Ovarian Neoplasms - drug therapy | Oncology, Experimental | Research | Cancer | Studies | Chemotherapy | Womens health | Vascular endothelial growth factor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Mutational analysis of circulating tumor cells from colorectal cancer patients and correlation with primary tumor tissue
by Lyberopoulou, Anna and Aravantinos, Gerasimos and Efstathopoulos, Efstathios P and Nikiteas, Nikolaos and Bouziotis, Penelope and Isaakidou, Athina and Papalois, Apostolos and Marinos, Evangelos and Gazouli, Maria
PLoS ONE, ISSN 1932-6203, 04/2015, Volume 10, Issue 4, p. e0123902
Circulating tumor cells (CTCs) provide a non-invasive accessible source of tumor material from patients with cancer. The cellular heterogeneity within CTC... 
STEM-CELLS | THERAPY | MULTIDISCIPLINARY SCIENCES | METASTASES | RESISTANCE | PERIPHERAL-BLOOD | KRAS | BRAF | MESENCHYMAL TRANSITION | CARCINOMA | CHEMOTHERAPY | Epithelial Cells - metabolism | Neoplastic Cells, Circulating - pathology | Colorectal Neoplasms - genetics | Humans | Middle Aged | Neoplastic Cells, Circulating - metabolism | Epithelial Cells - pathology | Male | Epithelial-Mesenchymal Transition - genetics | Feasibility Studies | Neoplastic Stem Cells - metabolism | DNA Mutational Analysis | Aged, 80 and over | Neoplastic Stem Cells - pathology | Adult | Female | Aged | Biomarkers, Tumor - genetics | Colorectal Neoplasms - pathology | Development and progression | Genetic aspects | Metastasis | Health aspects | Colorectal cancer | Immunoassay | Carcinoma | Profiling | Disease | Laboratories | Genomics | Colorectal carcinoma | Genomes | Biology | Kinases | Medical diagnosis | Cancer therapies | Metastases | Heterogeneity | Bioindicators | Growth factors | Deoxyribonucleic acid--DNA | Subpopulations | Tumor cells | Quantum dots | Invasiveness | Discordance | Feasibility studies | Patients | Medicine | Polymerase chain reaction | Chemotherapy | Hospitals | Restriction fragment length polymorphism | Biopsy | Stem cells | Biomarkers | Mutation | Tumors | Cancer | Deoxyribonucleic acid | DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
by Phelan, Catherine M and Kuchenbaecker, Karoline B and Tyrer, Jonathan P and Kar, Siddhartha P and Lawrenson, Kate and Winham, Stacey J and Dennis, Joe and Pirie, Ailith and Riggan, Marjorie J and Chornokur, Ganna and Earp, Madalene A and Lyra, Paulo C and Lee, Janet M and Coetzee, Simon and Beesley, Jonathan and McGuffog, Lesley and Soucy, Penny and Dicks, Ed and Lee, Anew and Barrowdale, Daniel and Lecarpentier, Julie and Leslie, Goska and Aalfs, Cora M and Aben, Katja K. H and Adams, Marcia and Adlard, Julian and Anulis, Irene L and Anton-Culver, Hoda and Antonenkova, Natalia and Aravantinos, Gerasimos and Arnold, Norbert and Arun, Banu K and Arver, Brita and Azzollini, Jacopo and Balmaña, Judith and Banerjee, Susana N and Barjhoux, Laure and Barkardottir, Rosa B and Bean, Yukie and Beckmann, Matthias W and Beeghly-Fadiel, Alicia and Benitez, Javier and Bermisheva, Marina and Bernardini, Marcus Q and Birrer, Michael J and Bjorge, Line and Black, Amanda and Blankstein, Kenneth and Blok, Marinus J and Bodelon, Clara and Bogdanova, Natalia and Bojesen, Anders and Bonanni, Bernardo and Borg, Åke and Bradbury, Angela R and Brenton, James D and Brewer, Carole and Brinton, Louise and Broberg, Per and Brooks-Wilson, Angela and Bruinsma, Fiona and Brunet, Joan and Buecher, Bruno and Butzow, Ralf and Buys, Sauna S and Caldes, Trinidad and Caligo, Maria A and Campbell, Ian and Cannioto, Rikki and Carney, Michael E and Cescon, Terence and Chan, Salina B and Chang-Claude, Jenny and Chanock, Stephen and Chen, Xiao Qing and Chiew, Yoke-Eng and Chiquette, Jocelyne and Chung, Wendy K and Claes, Kathleen B. M and Conner, Thomas and Cook, Linda S and Cook, Jackie and Cramer, Daniel W and Cunningham, Julie M and D'Aloisio, Aimee A and Daly, Mary B and Damiola, Francesca and Damirovna, Sakaeva Dina and Dansonka-Mieszkowska, Agnieszka and Dao, Fanny and Davidson, Rosemarie and Defazio, Anna and Delnatte, Capucine and Doheny, Kimberly F and Diez, Orland and Ding, Yuan Chun and Doherty, Jennifer Anne and Domchek, Susan M and Dorfling, Cecilia M and Dörk, Thilo and ... and KConFab Investigators and EMEMBRACE Study and GEMO Study Collaborators and OPAL Study Grp and AOCS Study Grp and HEBON Study and AOCS study group and EMBRACE Study and OPAL study group and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Ortopedi and Uppsala universitet and Institutionen för kirurgiska vetenskaper
Nature genetics, ISSN 1061-4036, 2017, Volume 49, Issue 5, pp. 680 - 691
To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping... 
BREAST-CANCER | COMMON VARIANTS | METAANALYSIS | CLEAR-CELL | ALGORITHM | GENETICS & HEREDITY | RISK | ASSOCIATION | CARCINOMA | ENDOMETRIOSIS | TELOMERE LENGTH | Neoplasms, Glandular and Epithelial - pathology | Genetic Predisposition to Disease - genetics | Genome-Wide Association Study | Meta-Analysis as Topic | Humans | Risk Factors | Genetic Loci - genetics | Ovarian Neoplasms - pathology | Genotype | Ovarian Neoplasms - genetics | BRCA1 Protein - genetics | Neoplasms, Glandular and Epithelial - genetics | Telomere-Binding Proteins - genetics | Alleles | Carcinoma, Ovarian Epithelial | Female | Polymorphism, Single Nucleotide | Mutation | BRCA2 Protein - genetics | Genetic susceptibility | Physiological aspects | Genetic aspects | Single nucleotide polymorphisms | Identification and classification | Health aspects | Risk factors | Ovarian cancer | Carriers | Medical research | Ovarian carcinoma | Genes | Gene regulation | Genomes | Breast cancer | Loci | Cancer | Life Sciences | Human health and pathology | Genetics | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: A hellenic cooperative oncology group clinical translational study
by Briasoulis, Evangelos and Aravantinos, Gerasimos and Kouvatseas, George and Pappas, Periklis and Biziota, Eirini and Sainis, Ioannis and Makatsoris, Thomas and Varthalitis, Ioannis and Xanthakis, Ioannis and Vassias, Antonios and Klouvas, George and Boukovinas, Ioannis and Fountzilas, George and Syrigos, Kostantinos N and Kalofonos, Haralambos and Samantas, Epaminontas
BMC Cancer, ISSN 1471-2407, 05/2013, Volume 13, Issue 1, pp. 263 - 263
Background: Metronomic chemotherapy is considered an anti-angiogenic therapy that involves chronic administration of low-dose chemotherapy at regular short... 
Metronomic-chemotherapy | Antiangiogenic | Vinorelbine | Cancer | ANGIOGENESIS | CYCLOPHOSPHAMIDE | GROUP HECOG | RECEPTOR | TOXICITY | CHEMOTHERAPY | THERAPY | ONCOLOGY | RESISTANCE | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Bone Neoplasms - secondary | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Liver Neoplasms - mortality | Dose-Response Relationship, Drug | Young Adult | Antineoplastic Agents, Phytogenic - administration & dosage | Vinblastine - analogs & derivatives | Biomarkers, Tumor - metabolism | Adult | Female | Bone Neoplasms - drug therapy | Liver Neoplasms - secondary | Real-Time Polymerase Chain Reaction | Prostatic Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Prostatic Neoplasms - pathology | Enzyme-Linked Immunosorbent Assay | Time-to-Treatment | Administration, Oral | RNA, Messenger - genetics | Translational Medical Research | Liver Neoplasms - drug therapy | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Breast Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Prostatic Neoplasms - mortality | Breast Neoplasms - pathology | Adolescent | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Drug therapy | Metastasis | Research | Care and treatment | Cancer patients | Chemotherapy | Oncology, Experimental | Fibroblast growth factors | Lung cancer, Non-small cell
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
by Fountzilas, George and Valavanis, Christos and Kotoula, Vassiliki and Eleftheraki, Anastasia G and Kalogeras, Konstantine T and Tzaida, Olympia and Batistatou, Anna and Kronenwett, Ralf and Wirtz, Ralph M and Bobos, Mattheos and Timotheadou, Eleni and Soupos, Nikolaos and Pentheroudakis, George and Gogas, Helen and Vlachodimitropoulos, Dimitrios and Polychronidou, Genovefa and Aravantinos, Gerasimos and Koutras, Angelos and Christodoulou, Christos and Pectasides, Dimitrios and Arapantoni, Petroula
Journal of Translational Medicine, ISSN 1479-5876, 01/2012, Volume 10, Issue 1, pp. 10 - 10
Background: HER2 and TOP2A parameters (gene status, mRNA and protein expression) have individually been associated with the outcome of patients treated with... 
Mrna expression | Anthracyclines | Gene amplification | Top2a | Randomized study | Cish | Early breast cancer | Taxanes | Her2 | TOP2A | early breast cancer | PREDICTIVE MARKERS | MEDICINE, RESEARCH & EXPERIMENTAL | CISH | TOPOISOMERASE-II-ALPHA | taxanes | IN-SITU HYBRIDIZATION | QUANTITATIVE PCR | ESTROGEN-RECEPTOR | mRNA expression | PARAFFIN-EMBEDDED TISSUE | MESSENGER-RNA | PROTEIN EXPRESSION | CELL-CYCLE | anthracyclines | HER2 | gene amplification | randomized study | Multivariate Analysis | Receptors, Estrogen - metabolism | Antibiotics, Antineoplastic - pharmacology | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Ki-67 Antigen - metabolism | Gene Expression Profiling | RNA, Messenger - metabolism | Receptors, Progesterone - metabolism | DNA-Binding Proteins - metabolism | Dose-Response Relationship, Drug | Paraffin Embedding | Young Adult | Poly-ADP-Ribose Binding Proteins | Breast Neoplasms - enzymology | Antigens, Neoplasm - metabolism | Adult | Female | Chemotherapy, Adjuvant | Gene Expression Regulation, Neoplastic - drug effects | Tissue Fixation | Genes, Neoplasm - genetics | Antigens, Neoplasm - genetics | DNA Topoisomerases, Type II - metabolism | RNA, Messenger - genetics | Risk Factors | Proportional Hazards Models | Treatment Outcome | DNA-Binding Proteins - genetics | Breast Neoplasms - drug therapy | Breast Neoplasms - genetics | Antibiotics, Antineoplastic - therapeutic use | Breast Neoplasms - pathology | Epirubicin - therapeutic use | DNA Topoisomerases, Type II - genetics | Aged | Epirubicin - pharmacology | Genes | Physiological aspects | Breast cancer | Genetic aspects | Research | Epirubicin | Drug therapy | Health aspects | DNA topoisomerase II | Medical research | Oncology | Cytotoxicity | Cancer therapies | Manuscripts | Medicine | Pathology | Chemotherapy | Hospitals | Writing | Drug dosages | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer
by Lampropoulou, Dimitra-Ioanna and Aravantinos, Gerasimos and Laschos, Konstantinos and Theodosopoulos, Theodosis and Papadimitriou, Christos and Gazouli, Maria
International Journal of Colorectal Disease, ISSN 0179-1958, 10/2019
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer
by Liamarkopoulos, Emmanouil and Gazouli, Maria and Aravantinos, Gerasimos and Tzanakis, Nikolaos and Theodoropoulos, George and Rizos, Spyros and Nikiteas, Nikolaos
Gastric Cancer, ISSN 1436-3291, 10/2011, Volume 14, Issue 4, pp. 317 - 321
Caspase-8 (CASP8) and caspase-9 (CASP9) play crucial roles in regulating apoptosis, and their functional polymorphisms may alter cancer risk. Our aim was to... 
Caspase 9 | Gene polymorphisms | Caspase 8 | Medicine & Public Health | Gastroenterology | Abdominal Surgery | Oncology | Cancer Research | Surgical Oncology | Gastric cancer | VARIANTS | RISK | PATHWAY CONFER SUSCEPTIBILITY | BREAST-CANCER | LUNG-CANCER | ONCOLOGY | CARCINOMAS | PROMOTER | GASTROENTEROLOGY & HEPATOLOGY | Caspase 8 - genetics | Stomach Neoplasms - genetics | Genetic Predisposition to Disease | Caspase 9 - genetics | Gene Frequency | Humans | Middle Aged | Female | Aged | Stomach Neoplasms - mortality | Case-Control Studies | Polymorphism, Genetic | Anopheles | Genes | Medical colleges | Genetic research | Genetic aspects | Disease susceptibility | Health aspects | Stomach cancer | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Significance of PIK3CA mutations in patients with early breast cancer treated with adjuvant chemotherapy: A Hellenic cooperative oncology group (HeCOG) study
by Papaxoinis, George and Kotoula, Vassiliki and Alexopoulou, Zoi and Kalogeras, Konstantine T and Zagouri, Flora and Timotheadou, Eleni and Gogas, Helen and Pentheroudakis, George and Christodoulou, Christos and Koutras, Angelos and Bafaloukos, Dimitrios and Aravantinos, Gerasimos and Papakostas, Pavlos and Charalambous, Elpida and Papadopoulou, Kyriaki and Varthalitis, Ioannis and Efstratiou, Ioannis and Zaramboukas, Thomas and Patsea, Helen and Scopa, Chrisoula D and Skondra, Maria and Kosmidis, Paris and Pectasides, Dimitrios and Fountzilas, George
PLoS ONE, ISSN 1932-6203, 10/2015, Volume 10, Issue 10, p. e0140293
Background The PI3K-AKT pathway is frequently activated in breast cancer. PIK3CA mutations are most frequently found in the helical (exon 9) and kinase (exon... 
ANDROGEN RECEPTOR | PTEN LOSS | TRASTUZUMAB | SIGNALING PATHWAY | RANDOMIZED PHASE-III | MULTIDISCIPLINARY SCIENCES | FACTOR RECEPTOR 2 | TENSIN HOMOLOG | DENSE SEQUENTIAL CHEMOTHERAPY | ASSOCIATION | PACLITAXEL | Prognosis | Signal Transduction | Humans | Middle Aged | Mutation Rate | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Young Adult | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Breast Neoplasms - pathology | Biomarkers, Tumor - metabolism | Adult | Female | Aged | Breast Neoplasms - diagnosis | Chemotherapy, Adjuvant | Mutation | Neoplasm Staging | Gene mutations | Adjuvant treatment | Physiological aspects | Breast cancer | Genetic aspects | Research | Drug therapy | Cancer | Immunohistochemistry | Statistical analysis | Carcinoma | Clinical trials | AKT protein | Histology | Statistical methods | Insulin-like growth factors | Kinases | Patients | ErbB-2 protein | Subgroups | 1-Phosphatidylinositol 3-kinase | Chemotherapy | Biomarkers | Breast | Sampling methods | Bioindicators | PTEN protein | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Abstract 2769: Response to 5FU therapy in colorectal cancer is affected by EZH2-mediated BclX splicing
by Benderska, Natalya and Gazouli, Maria and Aravantinos, Gerasimos and Hartmann, Arndt and Schneider-Stock, Regine
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 2769 - 2769
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Protein expression patterns of cell cycle regulators in operable breast cancer
by Zagouri, Flora and Kotoula, Vassiliki and Kouvatseas, George and Sotiropoulou, Maria and Koletsa, Triantafyllia and Gavressea, Theofani and Valavanis, Christos and Trihia, Helen and Bobos, Mattheos and Lazaridis, Georgios and Koutras, Angelos and Pentheroudakis, George and Skarlos, Pantelis and Bafaloukos, Dimitrios and Arnogiannaki, Niki and Chrisafi, Sofia and Christodoulou, Christos and Papakostas, Pavlos and Aravantinos, Gerasimos and Kosmidis, Paris and Karanikiotis, Charisios and Zografos, George and Papadimitriou, Christos and Fountzilas, George
PLoS ONE, ISSN 1932-6203, 08/2017, Volume 12, Issue 8, p. e0180489
Background-Aim To evaluate the prognostic role of elaborate molecular clusters encompassing cyclin D1, cyclin E1, p21, p27 and p53 in the context of various... 
OVEREXPRESSION | COOPERATIVE ONCOLOGY GROUP | PROGNOSTIC-FACTOR | EPIRUBICIN | RANDOMIZED PHASE-III | MULTIDISCIPLINARY SCIENCES | DENSE SEQUENTIAL CHEMOTHERAPY | INHIBITORS | P21 | P27(KIP1) | Immunohistochemistry | Prognosis | Cyclin-Dependent Kinase Inhibitor p27 - analysis | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Triple Negative Breast Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Young Adult | Cyclin D1 - analysis | Tumor Suppressor Protein p53 - analysis | Cyclin-Dependent Kinase Inhibitor p21 - analysis | Breast - drug effects | Breast Neoplasms - pathology | Triple Negative Breast Neoplasms - diagnosis | Cyclin E - analysis | Survival Analysis | Triple Negative Breast Neoplasms - pathology | Adult | Female | Aged | Breast Neoplasms - diagnosis | Oncogene Proteins - analysis | Breast - pathology | Usage | Analysis | Cell cycle | Clinical trials | Breast cancer | Research | Health sciences | GTP-binding protein | Regulators | Laboratories | Molecular clusters | p53 Protein | Oncology | Paraffin | Cyclin D1 | Kinases | Tissues | Cancer therapies | Formaldehyde | Cell adhesion & migration | Proteins | Medical research | Cyclin-dependent kinases | Clustering | Medicine | Pathology | Cyclin-dependent kinase inhibitor p21 | Hospitals | Medical prognosis | Breast | Tumors | Cancer | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study
by Papadimitriou, Christos A and Papakostas, Pavlos and Karina, Maria and Malettou, Lia and Dimopoulos, Meletios A and Pentheroudakis, George and Samantas, Epaminontas and Bamias, Aristotelis and Miliaras, Dimosthenis and Basdanis, George and Xiros, Nikolaos and Klouvas, George and Bafaloukos, Dimitrios and Kafiri, Georgia and Papaspirou, Irene and Pectasides, Dimitrios and Karanikiotis, Charisios and Economopoulos, Theofanis and Efstratiou, Ioannis and Korantzis, Ippokratis and Pisanidis, Nikolaos and Makatsoris, Thomas and Matsiakou, Fotini and Aravantinos, Gerasimos and Kalofonos, Haralabos P and Fountzilas, George
BMC Medicine, ISSN 1741-7015, 01/2011, Volume 9, Issue 1, pp. 10 - 10
Background: Colon cancer is a public health problem worldwide. Adjuvant chemotherapy after surgical resection for stage III colon cancer has been shown to... 
1ST-LINE TREATMENT | PLUS LEUCOVORIN | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | PERSPECTIVES | CAMPTOTHECINS | OXALIPLATIN | METASTATIC COLORECTAL-CANCER | FOLFIRI | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Dose-Response Relationship, Drug | Greece | Young Adult | Fluorouracil - therapeutic use | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Adult | Camptothecin - administration & dosage | Female | Leucovorin - therapeutic use | Chemotherapy, Adjuvant | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Treatment Outcome | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colonic Neoplasms - pathology | Aged | Neoplasm Staging | Chemotherapy | Usage | Colon cancer | Patient outcomes | Leucovorin | Drug therapy, Combination | Drug therapy | Health aspects | Fluorouracil | Cancer | Medical imaging | Heart attacks | Statistical analysis | Mortality | Colorectal cancer | Clinical trials | Histology | Cancer therapies | Manuscripts | Medicine | Hospitals | Tomography | Clinical medicine | Acquisitions & mergers | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site:A prospective retrospective translational study in the context of a hellenic cooperative oncology group randomised trial
by Pentheroudakis, George and Raptou, Georgia and Kotoula, Vassiliki and Wirtz, Ralph M and Vrettou, Eleni and Karavasilis, Vasilios and Gourgioti, Georgia and Gakou, Chryssa and Syrigos, Konstantinos N and Bournakis, Evangelos and Rallis, Grigorios and Varthalitis, Ioannis and Galani, Eleni and Lazaridis, Georgios and Papaxoinis, George and Pectasides, Dimitrios and Aravantinos, Gerasimos and Makatsoris, Thomas and Kalogeras, Konstantine T and Fountzilas, George
PLoS ONE, ISSN 1932-6203, 05/2015, Volume 10, Issue 5, p. e0124612
Background Although host immune response is an emerging prognostic factor for colorectal cancer, there is no consensus on the optimal methodology, surrogate... 
COLON-CANCER | LOCALIZATION | CELLS | METHYLATION | MULTIDISCIPLINARY SCIENCES | ESTROGEN | EPIDEMIOLOGY | Antigens, CD - immunology | Chemokines, CXC - immunology | Prognosis | Prospective Studies | Age Factors | Tissue Array Analysis | Colorectal Neoplasms - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Neoplasm Proteins - immunology | Male | Gene Expression Profiling | Estrogen Receptor alpha - immunology | Antigens, CD - genetics | Colorectal Neoplasms - diagnosis | Adult | Female | Adenocarcinoma - genetics | Retrospective Studies | Neoplasm Proteins - genetics | Transcription Factors - immunology | Colorectal Neoplasms - mortality | Adenocarcinoma - immunology | Lymphatic Metastasis | Transcription Factors - genetics | Chemokines, CXC - genetics | Immunity, Innate | Adenocarcinoma - diagnosis | Colorectal Neoplasms - immunology | Estrogen Receptor alpha - genetics | Survival Analysis | Heterozygote | Aged | Neoplasm Staging | Adenocarcinoma - mortality | Care and treatment | Chemotherapy | Analysis | Colorectal cancer | Genetic aspects | Gene expression | Cancer | Laboratories | CD8 antigen | Mucosa | Colorectal carcinoma | CXCL13 protein | Oncology | Necrosis | K-Ras protein | Metastases | ESR1 protein | Colon cancer | DNA methylation | Foxp3 protein | Colon | Localization | Immune system | Medical research | Immune response | Internal medicine | Invasiveness | Patients | CD4 antigen | Medicine | Cores | Pathology | Hospitals | DNA microarrays | Medical prognosis | Infiltration | Mutation | Snail protein | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights